Newsletter | September 15, 2026

09.15.26 -- Why Clinical Supply Problems Rarely Start In Clinical Supply

FEATURED EDITORIALS

First Advisors In: Meet Clinical Supply Leader's Inaugural Board Members

Clinical Supply Leader unveils its first Editorial Advisory Board, featuring leaders across clinical supply, quality, regulatory affairs, technology, and strategy.

 

Why Clinical Supply Problems Rarely Start In Clinical Supply

Clinical supply failures often start long before a stockout, when CMC, quality, regulatory, and clinical decisions create risks that supply teams inherit too late.

 

How To Build Clinical Supply Into Drug Development From The Start

Clinical supply can do more than execute development decisions. Bringing it in early can expose product, process, packaging, and patient-access risks while they can still be changed.

 

INDUSTRY INSIGHTS

 

Pharma Procurement Playbook: A Guide To Supplier Selection

Collaborative Sourcing’s Matthew Holt and Graham Phillipson share a cross-functional framework to help pharma leaders choose CDMOs and API manufacturers built for long-term success.

SOLUTIONS

Importer Of Record (IOR) Services For Clinical Trials

MORE GREAT EDITORIALS

Decision Authority And Direction — The Gap In Deviation Planning

Faster excursion detection improves supply visibility but also exposes an often-overlooked gap: a deviation plan outlining who has authority and what actions to take.

The Hidden Supply Chain Risks That Can Derail Small Biotech Trials

Small biotech trials face hidden supply risks that waste up to 75% of materials, delay timelines, and drain funding faster. Learn what causes them and how to prevent them.

Three Hidden ATMP Cold Chain Vulnerabilities By Design

Cold chain failures in ATMPs often stem from hidden design flaws, not execution errors. Learn how overlooked material, process, and preservation choices drive risk.